Xencor Inc
XNCR · XNASCIK 1326732fmd_0RZR42NX5KS24T0QJRXM4V83JTManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 109 | 46 | 41 | 157 | 123 | 275 | 165 | 175 | 110 | 126 |
| Net interest income | – | 4 | 9 | 14 | 7 | 1 | 5 | 19 | 32 | – |
| Research and development | 52 | 72 | 98 | 119 | 170 | 193 | 200 | 254 | 228 | 239 |
| Total operating expenses | 65 | 89 | 120 | 143 | 199 | 231 | 247 | 307 | 289 | 303 |
| Operating income | 44 | (43) | (79) | 14 | (77) | 44 | (82) | (132) | (178) | (178) |
| Interest expense | 0 | 0 | 0 | – | – | 0 | 0 | 6 | 37 | 32 |
| Interest and investment income | – | – | – | – | – | 1 | 5 | 19 | 32 | 28 |
| Other non-operating income (expense) | 2 | 4 | 9 | 13 | 7 | 39 | 28 | 13 | (57) | 88 |
| Income before taxes | 46 | (39) | (70) | 27 | (69) | 83 | (55) | (120) | (235) | (90) |
| Income tax expense | 1 | (0) | 0 | 0 | 0 | 0 | 1 | 14 | 2 | 3 |
| Net income from continuing operations | 45 | (38) | (70) | 27 | (69) | 83 | (55) | (133) | (237) | (92) |
| Net income | 45 | (38) | (70) | 27 | (69) | 83 | (55) | (133) | (233) | (92) |
| Net income to common shareholders | 45 | (38) | (70) | 27 | (69) | 83 | (55) | (133) | (233) | (92) |